Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Cases of Tourette Syndrome
4.2.2 Rising Focus on Tourette Syndrome Research
4.3 Market Restraints
4.3.1 Lack of Awareness in Developing Region
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Product
5.1.1 Antipsychotics
5.1.1.1 Haloperidol
5.1.1.2 Fluphenazine
5.1.1.3 Benzamide
5.1.1.4 Clozapine
5.1.1.5 Olanzapine
5.1.1.6 Others
5.1.2 Non Antipsychotics
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca Plc
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Eli Lilly and Co.
6.1.4 Mylan NV
6.1.5 Otsuka Holdings Co. Ltd.
6.1.6 Sanofi S.A.
6.1.7 Pfizer Inc.
6.1.8 Sun Pharmaceutical Industries Ltd
6.1.9 Neurocrine Biosciences, Inc.,
6.1.10 Novartis AG
6.1.11 Teva Pharmaceutical Industries Ltd.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS